Novan to Present Data from SB204 Phase 2b Trial at Fall Clinical Dermatology Conference
October 18 2016 - 9:05AM
Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today
announced that results from the Company’s Phase 2b clinical trial
to evaluate the efficacy and safety of topical nitric
oxide-releasing product candidate SB204 gel for the treatment of
acne vulgaris, or acne, will be presented at the 35th Anniversary
Fall Clinical Dermatology Conference in Las Vegas. This
presentation will include the results of efficacy assessments and
additional data regarding the tolerability of SB204 throughout the
12-week trial.
“In more than 30 years of experience as a
dermatologist, I have seen firsthand how the tolerability of a
topical acne product drives patient compliance," said M. Joyce
Rico, MD, Chief Medical Officer of Novan. “The safety and
tolerability profile observed in the Phase 2b clinical trial with
SB204 was excellent. Of all five tolerability assessments, the
burning/stinging and scaling categories reflected the most notable
difference between active and vehicle. Patients treated with SB204
rarely developed moderate (<3%) or severe (1%) burning/stinging
at any point during treatment, while the incidence of moderate
scaling never exceeded 1%.”
Novan announced in September that the Company’s
two, identically designed Phase 3 pivotal clinical trials for SB204
were fully enrolled. Novan expects to report top-line results from
these Phase 3 trials in the first quarter of 2017.
About the Presentation
Title: “Efficacy and Safety of
SB204 Gel in the Treatment of Acne Vulgaris”Lead
Author: Lawrence Eichenfield, MD, Chief of Pediatric and
Adolescent Dermatology at San Diego Children’s Hospital and
Clinical Professor of Pediatrics and Medicine at the University of
California, San Diego School of MedicineAbstract/Poster
Number: to be assigned at the start of the Conference
Dates: Thursday-Sunday, Oct. 20-23, 2016
About Novan
Novan, Inc. is a late-stage pharmaceutical
company focused on redefining the standard of care in dermatology
through the development and commercialization of innovative
therapies using the Company’s nitric oxide-releasing platform.
Nitric oxide plays a vital role in the natural immune system
response against microbial pathogens and is a critical regulator of
inflammation. Our ability to harness nitric oxide and its multiple
mechanisms of action has enabled us to create a platform with the
potential to generate differentiated, first-in-class product
candidates. We are rapidly advancing programs in five
dermatological conditions with significant unmet medical need. We
believe that our ability to conveniently deploy nitric oxide on
demand in topical formulations allows us the potential to
significantly improve patient outcomes in a variety of skin
diseases and positions us to be a commercially successful leader in
the dermatology market.
For more information, visit the Company’s
website at www.Novan.com.
Forward-Looking Statements
This press release contains forward-looking
statements including, but not limited to, statements related to
pharmaceutical development of nitric oxide-based product candidates
and future prospects. Forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from our expectations. These forward-looking
statements speak only as of the date of this press release, and
Novan disclaims any intent or obligation to update these
forward-looking statements, except as expressly required by
law.
CONTACT:
(Investors)Sean Andrews, Senior Director of Investor
RelationsNovan, Inc.919-627-6847investors@novan.com
(Media)Deb HollidayPascale Communications,
LLC412-877-4519deb@pascalecommunications.com
Novan (NASDAQ:NOVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novan (NASDAQ:NOVN)
Historical Stock Chart
From Apr 2023 to Apr 2024